Treatment potential in APOL1-associated nephropathy

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Over 5 million African-Americans carry APOL1 high-risk genotypes, significantly increasing susceptibility to chronic kidney disease (CKD).
• APOL1 gene variants are a primary cause of nondiabetic nephropathy in individuals of sub-Saharan African ancestry.
• Conventional treatments for APOL1-associated nephropathy often yield suboptimal outcomes.

Purpose of the Study:

• To review current and emerging treatment strategies for slowing the progression of APOL1-associated nephropathy.
• To highlight the limitations of existing therapies and the potential of novel therapeutic approaches.

Main Methods:

• Review of recent findings on APOL1-associated nephropathy.
• Analysis of treatment outcomes for conventional and targeted therapies.
• Emphasis on the role of APOL1 genotyping and kidney biopsy in clinical practice.

Main Results:

• Aggressive hypertension control and renin-angiotensin system blockade are insufficient for APOL1-associated nephropathy.
• APOL1-mediated collapsing glomerulopathy can resolve with cessation of offending agents (e.g., interferon, antiretroviral therapy).
• Targeted therapies, including APOL1 small molecule inhibitors, APOL1 antisense oligonucleotides (ASO), and anti-inflammatory agents, demonstrate significant therapeutic potential.

Conclusions:

• APOL1-associated nephropathy encompasses diverse phenotypes linked by specific APOL1 genetic variants.
• Clinical trials investigating small molecule inhibitors, ASO, and inflammatory pathway inhibitors are crucial for improving patient outcomes.
• Increased utilization of APOL1 genotyping and kidney biopsy is recommended to guide treatment decisions and advance research.